To perform a pilot study on patients with progressive G2/3 glioma after treatment with radiotherapy and chemotherapy, who consent to resection of tissue for molecular typing or analysis of tissue resected at surgery within six months prior to enrolment, with a view of treatment with matched targeted agents where available, or else treatment with standard of care therapies.

HMRC Clinical Trials Centre (CTC), University of Sydney0 个研究点目标入组 10 人开始时间: 2020年2月3日最近更新: 2023年6月26日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 10

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Observational

入排标准

年龄范围: 18 Years 至 o limit（—）
性别: All

入选标准

•1. Adults, aged 18 years and older, with histological confirmed grade 2 or 3 glioma at initial diagnosis.
•2. Prior to last craniotomy and surgery, evidence of progressive disease as defined as evidence of new contrast-enhancing tumour and/or 25% increase in the size of the T2/FLAIR area compared to prior imaging after prior treatment with radiotherapy and chemotherapy.
•3. Has available tissue from resection for progressive disease for molecular profiling either within 6 months of study enrolment or following enrolment.
•4. For patients who are undergoing standard of care surgery at the time of study entry:
•a. The patient must be suitable for craniotomy as the opinion of the neurosurgical team who will perform the surgery.
•b. In the opinion of the neurosurgical team, it will be possible to safely undertake a debulking procedure and that sufficient tissue will be obtained for molecular testing
•c. Has substantially recovered from their surgical resection, as evidenced by having no major on-going safety issues (e.g. infection requiring antibiotics)
•5. Patients who have already undergone standard of care surgery less than or equal to 6 months prior to study registration, there must be sufficient tissue available for molecular testing and the patient must not have had intervening anti-cancer therapy.
•6. Dose at registration must be less than or equal to 20mg prednisolone or less than or equal to 3 mg dexamethasone daily (or equivalent). Patients who are not on steroids are preferred for study participation.
•7. ECOG performance status 0-2.
•8. Has measurable disease post their last craniotomy that is suitable for repeat assessment by MRI scans.
•9. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.
•10. Signed, written informed consent (main study and tissue banking).

排除标准

•1. Glioma tissue for molecular pathology obtained greater than or equal to 6 months prior to study entry
•2. Any intervening systemic therapy or radiotherapy between most recent imaging showing progressive disease and study enrolment
•3. Patients who have had intra-surgical treatments (e.g. oncolytic virus administration, Gliadel wafers) at their last craniotomy prior to study enrolment
•4. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
•5. Subjects unable (e.g. due to pacemaker or ICD device) or unwilling to have a contrast-enhanced MRI of the head.
•6. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.

研究者

发起方

HMRC Clinical Trials Centre (CTC), University of Sydney

相似试验

已完成

不适用

Pilot study to establish the treatment of patients with frailty and sarcopenia using the device of promoting neural control of paravertebral muscleower back pain patients with frailty/sarcopenia, or having muscle weakness in their previous stage

JPRN-UMIN000029803Fukuoka University Hospital8

已完成

不适用

Pilot study to assess the feasibility and patient numbers required prior to a randomised controlled trial of the effect of visual distraction for painful procedures in the burns unit

ISRCTN69643568Department of Health10

招募中

不适用

Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drugProgressive supranuclear palsy

JPRN-UMIN0000365221) Department of Neurology, Gifu University Graduate School of Medicine, 2) National Hospital Organization, Higashi Nagoya Hospital32

尚未招募

2 期

A Study to find the Effectiveness of Siddha treatment for Vathakarsanam (Diabetic Peripheral Neuropathy)

CTRI/2024/06/069492I

尚未招募

2 期

Herbo-Mineral Solution having potential antimicrobial properties in cleansing of infected wounds.

CTRI/2023/11/060378DepartmParul Institute Of Ayurveda Parul University Waghodia Road Vadodara Gujarat India